Galectin Therapeutics (NASDAQ:GALT – Get Free Report) and Stevanato Group (NYSE:STVN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
Valuation and Earnings
This table compares Galectin Therapeutics and Stevanato Group”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Galectin Therapeutics | N/A | N/A | -$30.84 million | ($0.41) | -12.12 |
| Stevanato Group | $1.20 billion | 4.48 | $158.21 million | €0.59 | 30.15 |
Insider & Institutional Ownership
11.7% of Galectin Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Galectin Therapeutics and Stevanato Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Galectin Therapeutics | N/A | N/A | -164.69% |
| Stevanato Group | 11.76% | 10.27% | 6.08% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Galectin Therapeutics and Stevanato Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Galectin Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Stevanato Group | 0 | 2 | 3 | 2 | 3.00 |
Galectin Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 121.33%. Given Galectin Therapeutics’ higher possible upside, equities analysts plainly believe Galectin Therapeutics is more favorable than Stevanato Group.
Volatility and Risk
Galectin Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Summary
Stevanato Group beats Galectin Therapeutics on 11 of the 14 factors compared between the two stocks.
About Galectin Therapeutics
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
